Jan 25, 2023

Public workspaceA human development-based protocol for the differentiation of human ESCs into midbrain dopaminergic neurons.

This protocol is a draft, published without a DOI.
A human development-based protocol for the differentiation of human ESCs into midbrain dopaminergic neurons.
  • Kaneyasu Nishimura1,
  • Emilia Síf Ásgrimsdottir1,
  • Shanzheng Yang1,
  • Ernest Arenas1
  • 1Karolinska Institutet, Department of Medical Biochemistry and Biophysics, Laboratory of Molecular Neurobiology, Stockholm 171 77, Sweden
Open access
Protocol CitationKaneyasu Nishimura, Emilia Síf Ásgrimsdottir, Shanzheng Yang, Ernest Arenas 2023. A human development-based protocol for the differentiation of human ESCs into midbrain dopaminergic neurons.. protocols.io https://protocols.io/view/a-human-development-based-protocol-for-the-differe-cmftu3nn
Manuscript citation:
Nishimura K, Yang S, Lee KW, Ásgrímsdóttir ES, Nikouei K, Paslawski W, Gnodde S, Lyu G, Hu L, Saltó C, Svenningsson P, Hjerling-Leffler J, Linnarsson S, Arenas E. Single-cell transcriptomics reveals correct developmental dynamics and high-quality midbrain cell types by improved hESC differentiation. Stem Cell Reports. 2022 Nov 8:S2213-6711(22)00512-4. doi: 10.1016/j.stemcr.2022.10.016
License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License,  which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Protocol status: Working
We use this protocol and it's working
Created: January 08, 2023
Last Modified: January 25, 2023
Protocol Integer ID: 74963
Keywords: Human, midbrain, dopamine, neuron, embryonic stem cell, progenitor, differentiation, maturation, function, single cell, RNA-sequencing, development, Parkinson's disease, cell replacement, disease modeling, cell type
Funders Acknowledgement:
Chan Zuckeberg Initiative and the Silicon Valley
Grant ID: 2018-191929
ERC advanced grant
Grant ID: 884608
Neurostemcell-reconstruct
Grant ID: H2020, 874758
Knut and Alice Wallenberg Foundation
Grant ID: KAW scholar 2018.0232
Swedish Foundation for Strategic Research
Grant ID: SSF, SB16-0065
Karolinska Institutet StratRegen
Grant ID: SFO2018
Vetenskapsrådet
Grant ID: 2020-01426
Hjärnfonden
Grant ID: FO2019-0068 and PS2018-0043
Krolinska Institutet KID Grant to ESA
Grant ID: 2-5996/2018
Japan Society for the Promotion of Science (JSPS) KAKEN
Grant ID: 22K07382
Abstract
Protocol for the differentiation of human embryonic stem cells into midbrain dopaminergic neurons. This protocol recapitulates the activation of developmental pathways known to be important for mDA neuron development and mimics key sequence of events taking place in human midbrain development.

The protocol involves activation of not only Shh and WNT/b-catenin signaling, but also the sequential activation of additional pathways that have not been previously implemented in hESC differentiation, including: activation of non-canonical WNT signaling by WNT5A, of integrin/YAP signaling by Laminin 511, and of the nuclear receptors NR1H3 and NR1H2 by GW3965.

In an accompanying publication (Nishimura et al., 2022; doi: 10.1016/j.stemcr.2022.10.016) single cell RNA-sequencing is used to confirm:
(i) that the cells generated in vitro follow critical developmental steps as endogenous human midbrain DA neurons in vivo,
(ii) that contaminating/inappropriate cells (from outside the ventral midbrain) are not present in the cultures, and
(iii) that the quality of the cells in vitro is comparable to that of endogenous human ventral midbrain developmental standards in vivo.
Additional experiments show that the neurons are functional in vitro, as assessed by electrohysiological properties and dopamine release. We conclude that this differentiation protocol models human midbrain DA neuron development in vitro. We suggest a possible application of this protocol to generate either DA progenitors for cell replacement in Parkinson's disease (PD) or DA neurons for in vitro modeling of PD and drug testing in human PD-iPS cells.
Image Attribution
Image taken by Emilia Síf Ásgrimsdottir showing MAP2 (green), TH (red) and DAPI (bue) in a culture differentiated for 28 days.
Materials
List of reagents
ABC
Reagent Source Cat. no
Nutristem hPSC XF Saveen-Werner 05-100-1A
TeSR™-E6 STEMCELL Technologies 05946
Neurobasal™ Medium Thermo Scientific 21103049
Y27632 Tocris 1254
LDN193189 Stemgent 04-0074-base
SB431542 Tocris 1614/10
Purmorphamine Tocris 4551
CHIR99021 Sigma Aldrich SML1046
WNT5A R&D 645-WN
FGF8B Peprotech 100-25-100
BDNF R&D 248-BDB-010
Ascorbic Acid Sigma-Aldrich A4403
DAPT Tocris 2634
GW3965 Sigma-Aldrich G6295
GDNF R&D 212-GD-010/CF
dbcAMP Sigma-Aldrich D0627-1G
TGFb3 R&D 243-B3-010/CF
PD0325901 Sigma-Aldrich PZ0162
SU5402 Sigma-Aldrich SML0443
Laminin 511 Laminin 521 Biolamina LN511-0502 LN521-05
B27 Thermo Scientific 17504044
L-Glutamine Thermo Scientific 25030081
NEAA Thermo Scientific 11140035
2-Mercaptoethanol Thermo Scientific 31350010
TrypLE Select Thermo Scientific 12604021
Defined Trypsin Inhibitor Thermo Scientific R007100
DNase I Sigma-Aldrich 11284932001

Safety warnings
Attention
PLease check each of the reagents before usage.
Before start
Prepare the culture media

E6 media
TesR-E6 500 mL
L-Glutamine 5 mL (x100)
NEAA 5 mL (x100)
50 mM 2-ME 1 mL (x500)

Neurobasal media
Neurobasal 500 mL
L-Glutamine 5 mL (x100)
B27 10 mL (x50)


Coating of the well of choice

ABCDEF
96-well 48-well 24-well 12-well 6-well
Surface area (0.33cm2) (0.75cm2) (1.82cm2) (3.8cm2) (9.6cm2)
Laminin (521 for hESCs or 511 for DA differentiation) 3.2 uL 10 uL 20 uL 40 uL 100 uL
DPBS(+/+) 50 uL 150 uL 300 uL 600 uL 1500 uL
Maintenance of hESCs cells
Maintenance of hESCs cells
Prior to the start of differentiation, hESCs are cultured in NutriStem® XF media on LN521 (1 ug/cm2) coated plates. Once the cells reach approximately 70-90% confluency, cells are passaged at a seeding density of 20.000 cells/cm2 with ROCK inhibitor (10 uM Y-27632), only during the first 24h.
Prior to the passage of hESCs, prepare the LN521 coated plate by diluting LN521 (1 ug/cm2) in a sufficient volume of DPBS (+/+) to completely cover the well. Incubate the plate for a minimum of 2h at 37°C or overnight at 4°C. Before seeding the cells, wash the coated plates two times with DPBS (+/+). Laminin coated plates can be wrapped in Parafilm and stored for up to two weeks at 4°C

To passage the hESCs, remove the media and wash the cells once with DPBS(-/-). Add pre-warmed TrypLE (100 uL/cm2) to the cells and incubate at 37°C for 4 minutes. After 4 minutes, disassociate the cells by gently pipetting up and down using a 1 mL pipette to yield a single cell solution. Inactivate the TrypLE by either adding pre-warmed defined trypsin inhibitor in a 1:1 ratio to the TrypLE or by diluting the TrypLE in a 1:5 ratio with NutriStem® XF medium with ROCK inhibitor (10 uM Y-27632).

Remove a 10 uL aliquot for counting and count cells using either a hemocytometer or an automated cell counter. Determine the required volume of cell suspension needed to achieve a plating density of 20.000 cells/cm2 and then spin down the cells at 1200 rpm for 5 minutes at RT. After spinning, aspirate the medium and re-suspend the cells in NutriStem® XF with ROCK inhibitor (10 uM Y-27632) and plate the cells on pre-warmed LN521 coated plates.


Midbrain DA differentiation of hESCs
Midbrain DA differentiation of hESCs
To start the differentiation protocol, passage the hESCs onto a LN511 coated (1 ug/cm2) plate according to the protocol outlined above . Cells are plated at a seeding density of 500.000 cells/cm2 and the media volume is approximately 1mL/cm2. In the first 11 days of the protocol it is normal and expected that the media becomes orange-yellow overnight but if it becomes completely yellow it may be good to increase the media volume slightly.

The example protocol below is given for a differentiation done in a 12 well plate.
Day -2
Cells are plated in NutriStem® XF + 10 uM Y-27632
Day -1
Add fresh NutriStem® XF media.

Cells should be very dense, covering the bottom of the well completely and the media should have turned orange overnight.
Day 0
Cultivate cells in: Volume (stock)
Essential 6™ media 4 mL
0.5 mM LDN193189 1.6 uL (x2500)
10 mM SB431542 4 uL (x1000)
10 mM Y27632 2 uL (x2000)
Days 1-2
Cultivate cells in: Volume (stock)
Essential 6™ media 4 mL
0.5 mM LDN193189 1.6 uL (x2500)
10 mM SB431542 4 uL (x1000)
2 mM Purmorphamine 4 uL (x1000)

As the cells are plated very densely at the start of the protocol, it is common to observe some shrinkage at the outer ring of the well. If this happens, it is very important to remove and add the media gently, using a 1 mL pipette. If the shrinkage is severe at the time of changing media, it usually helps to only remove the media partially, leaving enough old media to just barely cover the cells.
Days 3-4
Cultivate cells in: Volume (stock)
Essential 6™ media 4 mL
0.5 mM LDN193189 1.6 uL (x2500)
10 mM SB431542 4 uL (x1000)
2 mM Purmorphamine 4 uL (x1000)
1mM CHIR99021 6 uL (x667)
Days 5-6
Cultivate cells in: Volume (stock)
Essential 6™ media 3 mL
Neurobasal™ media 1 mL
0.5 mM LDN193189 1.6 uL (x2500)
10 mM SB431542 4 uL (x1000)
2 mM Purmorphamine 4 uL (x1000)
1mM CHIR99021 6 uL (x667)
Days 7-8
Cultivate cells in: Volume (stock)
Essential 6™ media 2 mL
Neurobasal™ media 2 mL
0.5 mM LDN193189 1.6 uL (x2500)
2 mM Purmorphamine 4 uL (x1000)
1mM CHIR99021 6 uL (x667) 100 ug/ml WNT5A 4 ul (x1000)
Days 9-10
Cultivate cells in: Volume (stock)
Essential 6™ media 1 mL
Neurobasal™ media 3 mL
0.5 mM LDN193189 1.6 uL (x2500)
2 mM Purmorphamine 4 uL (x1000)
1mM CHIR99021 6 uL (x667) 100 ug/ml WNT5A 4 ul (x1000) 100 ug/mL FGF8B 4 ul (x1000)
Coat a plate with LN511 (1 ug/cm2) ahead of re-plating on D11 at 4°C overnight.
Day 11 (Replating cells at 500.000 cells/cm2)

Pre-warm the LN511 coated plated for one hour at 37°C. Wash the coated wells twice with DPBS (+/+) before plating the cells.

Wash cells once with DPBS(-/-) and add 500 uL of TrypLE Select with DNase I (100 ug/mL). Incubate the cells at 37°C for 10-15 min and then dissociate the cells with a 1 mL pipette to yield a single cell solution.

When the cells are dissociated, inactivate the TrypLE by adding either pre-warmed defined trypsin inhibitor with DNAseI (100 ug/mL) in a 1:1 ratio to the TrypLE or by diluting the TrypLE in a 1:5 ratio with Neurobasal medium with ROCK inhibitor (10 uM Y-27632).

Remove a 10 uL aliquot for counting and count cells using either a hemocytometer or an automated cell counter. Determine the required volume of cell suspension needed to achieve a plating density of 500.000 cells/cm2 and then spin down the cells at 1200 rpm for 5 minutes at RT. After spinning, aspirate the medium and re-suspend the cells in the following media.

Neurobasal™ media 4 mL
2 mM Purmorphamine 4 uL (x1000)
10 mM CHIR99021 3 uL (x1333) 100 ug/mL FGF8B 4 ul (x1000) 10 mM Y27632 4 uL (x1000)
Days 12-15
Cultivate cells in: Volume (stock)
Neurobasal™ media 4 mL
2 mM Purmorphamine 4 uL (x1000)
10 mM CHIR99021 3 uL (x1333) 100 ug/mL FGF8B 4 ul (x1000)
Coat a plate with LN511 (1 ug/cm2) ahead of re-plating on D16 at 4°C overnight.

Day 16 (Replating cells at 500.000 cells/cm2)
On D16, cells are re-plated following the same protocol as detailed on D11 and then re-suspended in:

Neurobasal™ media 4 mL
20 ug/mL BDNF 4 uL (x1000)
200 mM AA 4 uL (x1000)
10 mM DAPT 4 uL (x1000)
10 mM GW3965 4 uL (x1000)
10 mM Y27632 4 uL (x1000)
Days 17-21
Cultivate cells in: Volume (stock)
Neurobasal™ media 4 mL
20 ug/mL BDNF 4 uL (x1000)
200 mM AA 4 uL (x1000)
10 mM DAPT 4 uL (x1000)
10 mM GW3965 4 uL (x1000)
Optional re-plating step: cells can be re-plated on D22 following the same procedure as detailed on D11. This re-plating step is not necessary but it can be beneficial to replenish the LN511 and standardize the cell number if the cells are cultivated beyond D28 of the protocol.

Days 22-27
Cultivate cells in: Volume (stock)
Neurobasal™ media 4 mL
20 ug/mL BDNF 4 uL (x1000)
20 ug/mL GDNF 2 uL (x2000)
500 mM dbcAMP 4 uL (x1000)
200 mM AA 4 uL (x1000)
2 ug/mL TGFb3 2 uL (x2000)
1 mM PD0325901 4 uL (x1000)
5 mM SU5402 4 uL (x1000)
10 mM DAPT 4 uL (x1000)
Days 28- 75: Final maturation (Only half media changes from this point onwards to reduce the risk of cell detachment)
Cultivate cells in: Volume (stock)
Neurobasal™ media 4 mL
20 ug/mL BDNF 4 uL (x1000)
20 ug/mL GDNF 2 uL (x2000)
500 mM dbcAMP 4 uL (x1000)
200 mM AA 4 uL (x1000)
2 ug/mL TGFb3 2 uL (x2000)
10 mM DAPT 4 uL (x1000)